Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that three submitted abstracts were accepted for the 106^th Annual Meeting of the Endocrine Society (ENDO 2024) taking place June 1-4, 2024, in Boston.

In a poster presentation, the company will present final results from its Phase 2 POWER study of tildacerfont for the treatment of polycystic ovary syndrome (PCOS). In two other poster presentations, the company will highlight the comorbidities associated with congenital adrenal hyperplasia (CAH) and standard of care treatment, as well as the need to formalize transitionary care between pediatric and adult endocrinology practices to improve biochemical outcomes that reduce the risk of morbidity and mortality in adults with CAH.

ENDO 2024 Poster Presentation Details

Title: A Randomized, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of Tildacerfont in Adult Subjects with Polycystic Ovary Syndrome (PCOS) and Elevated Adrenal Androgens

Session Title: P058 – Reproductive Endocrinology: Polycystic Ovary Syndrome

Session Date & Time: 12:00 – 1:30 p.m. ET on June 2, 2024

Presenter: Ricardo Azziz, M.D., M.B.A., M.P.H., Professor, Obstetrics and Gynecology at University of Alabama at Birmingham School of Medicine

Authors: Yvette M. Poindexter, M.D., FACOG, M.B.A.; Maralisa Vanandel, BCPA, Daniel A. Dumesic, M.D.; Ricardo Azziz, M.D., M.B.A., M.P.H.; Richard Joseph Auchus, M.D., Ph.D.; Will Charlton, M.D.; Saba Sile, M.D.; Lubna Pal, MBBS, FRCOG

Title: Impact of Geography and Insurance on Healthcare Utilization Preferences of Individuals with Congenital Adrenal Hyperplasia

Session Title: P023 – Adrenal (Excluding Mineralocorticoids): Health Disparities in Adrenal

Session Date & Time: 12:15 – 1:45 p.m. ET on June 1, 2024

Presenter: Prasanth Surampudi, M.D., Associate Professor, Endocrinology, Diabetes, and Metabolism at U.C. Davis School of Medicine

Authors: Prasanth Surampudi, M.D.; Amir Hamrahian, M.D.; Will Charlton, M.D.; PJ Ramtin; Mitchell Geffner, M.D.

Title: The Treatment May Be Worse Than the Disease: The Real-World Clinical Burden of Disease and Treatment in Congenital Adrenal Hyperplasia

Session Title: P023 – Adrenal (Excluding Mineralocorticoids): Health Disparities in Adrenal

Session Date & Time: 12:15 – 1:45 p.m. ET on June 1, 2024

Presenter: Wenyu Huang, M.D., Ph.D., Associate Professor, Division of Endocrinology, Metabolism, and Molecular Medicine at Northwestern University Feinberg School of Medicine, and Amir Hamrahian, M.D., Associate Professor of Medicine, Division of Endocrinology, Diabetes and Metabolism at John Hopkins University

Authors: Wenyu Huang, M.D., Ph.D.; Will Charlton, M.D.; Saba Sile, M.D.; Christopher Dieyi, M.B.A., M.P.H.; Shayna Adams, M.P.H.; Jason Maynard, Ph.D.; Chris Barnes, Ph.D.; Amir Hamrahian, M.D.

The poster presentations will be available on the company’s website at the time of their respective poster sessions. Access more information about ENDO 2024 here.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH) and other endocrine disorders. To learn more, visit www.sprucebio.com and follow us on Twitter/X @Spruce_Bio, LinkedIn, Facebook and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240522604348/en/